Name: | gemtuzumab ozogamicin |
---|---|
Name (isomeric): | DB00056 |
Drug Type: | biotech |
Synonyms: |
anti-CD33; Mylotarg
|
Brand: | Mylotarg (Wyeth), Mylotarg |
Category: | Antineoplastic Agents |
CAS number: | 220578-59-6 |
Indication: | For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy. |
---|---|
Pharmacology: |
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cell...
show more » |
Mechanism of Action: |
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin de...
show more » |
Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system. |
Toxicity: | The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder. |
Affected organisms: | Humans and other mammals |